Many board members now act as extensions of the executive team. They support founders and CEOs with real‑time problem solving, introductions to capital and partners, and hands‑on guidance across clinical strategy, regulatory navigation, M&A readiness, and talent decisions. Chairs, in particular, are increasingly expected to act as CEO coaches, helping first‑time leaders transition from science‑led entrepreneurs to scalable business builders while maintaining investor confidence and organisational focus.

This hands‑on approach is especially evident in early‑ to mid‑stage companies, where governance and execution blur by necessity. Investors actively seek board members who have “been there before”: leaders who have taken assets through clinical inflection points, built organisations through rapid growth, or navigated failed trials and resets. The modern board is judged as much on its operational contribution as its independence.

For executive search, this evolution has profound implications. The bar for board appointments is higher than ever, with far greater emphasis on lived operating experience, resilience, and chemistry with management teams. The most impactful Chairs and NEDs today are not just stewards of governance, they are instant impact and consistent value add.

Critical roles such as Chief Technology Officer, Head of Computational Biology, Principal AI Scientist, and hybrid scientific‑commercial leaders are in chronically short supply. These individuals must combine deep domain expertise with the ability to operate in fast‑moving, cross‑functional environments, something that cannot be solved through compensation alone. Purpose, platform credibility, and the quality of leadership are now decisive factors in attracting elite candidates.

At the executive level, competition has intensified further as companies seek leaders who can bridge science and scale. Boards and investors are prioritising executives who have operated across both biotech and technology ecosystems, leaders comfortable with agile development, data‑driven decision‑making, and partnering models. This has sharply increased demand for a relatively small pool of proven crossover talent.

Winning in this environment requires a far more thoughtful and proactive approach to talent strategy. Successful organisations are engaging earlier, building long‑term relationships with future leaders, and using executive search not simply to fill roles, but to shape leadership architecture ahead of growth. In today’s market, access to the right talent is not a support function, it is a core competitive advantage.

Investors are increasingly prioritising differentiated platforms over single‑asset stories, particularly where technology can unlock multiple shots on goal or materially reduce development risk. Assets that combine strong biological rationale with enabling technologies, such as AI, novel modalities, or scalable manufacturing, continue to attract attention. However, the science must be accompanied by robust validation, clear development plans, and leadership teams with proven delivery track records.

Management quality has emerged as a decisive investment factor. Investors are scrutinising leadership depth earlier, evaluating whether teams can survive clinical setbacks, pivot strategically, and build organisations capable of partnering or exiting. Boards that bring real operating credibility and networks are viewed as material de‑risking factors, not governance formalities.

Looking ahead, investors are bullish on companies that demonstrate focus, realism, and execution excellence. Those that can show disciplined capital use, strong decision‑making, and the ability to attract top‑tier talent will continue to secure funding, even in challenging markets. In this environment, leadership and talent are not just inputs to growth; they are central to the investment thesis itself.